Treatment for inflammatory and allergic disorders (IPP-201007)

IPP-201007 is a new molecule that has the potential to become a PLA2 inhibitor, reducing some allergic reactions and helping to fight targeted inflammatory disorders.


Phospholipases A2 (PLA2s) are enzymes that catalyse the hydrolysis of phospholipids. This catalytic reaction is essential in the production of lipids during various processes in the body, involving prostaglandins, leukotrienes, thromboxanes, platelet activation factor and others.  

In certain cases, such lipid mediators cause allergic reactions and a number of inflammatory conditions such as asthma and other respiratory disorders, rheumatoid arthritis, septic shock and acute pancreatitis which are characterised by a significant increase in PLA2 activity.

How ImmuPharma’s inflammatory disorders treatment may work

Selective inhibition of PLA2 subtypes can reduce some of these allergic reactions, and inhibitors of PLA2 have already been shown to have positive effects in inflammatory conditions. ImmuPharma believes this new molecule has the potential to treat certain inflammatory conditions and intends to progress its development.